RECHARGEABLE CELL CONTAINMENT DEVICE--PANCREATIC ISLET

维持平衡应防止发展;或停止 糖尿病并发症的发展。 外源性胰岛素治疗在产生一致的， 长期的欧胰腺组织置换已经显示出令人鼓舞的 但迄今为止，由于供体器官短缺，技术 手术的并发症，宿主的免疫反应，以及 所需免疫抑制药物的感染和并发症 疗法生物人工胰腺提供了一种潜在的解决方案， 对所含胰岛组织的免疫保护作用。这将允许使用 异种胰岛组织而不需要免疫抑制。的 PI已经开发出一种细胞容纳装置，该装置已被证明：1） 将异种胰岛与宿主免疫隔离，2）使胰岛 生产胰岛素并保持活力长达43天，3）易于交换 在没有外科手术干预的情况下， 功能，4）避免器件封装。 该第一阶段提案将证明该器械用于以下器械的可行性： 猪胰岛在研究犬中实现正常生长的作用，以评估 裸胰岛与微囊化胰岛的效率， 设备.

The maintenance of euglycemia should prevent the development of; or halt the progression of secondary complications of Diabetes Mellitus. Exogenous insulin therapy has been unsuccessful in producing consistent, long term euglycemia. Pancreatic tissue replacement has shown encouraging results but is limited to date by the shortage of donor organs, technical complications of the surgery, the immune response of the host, and infections and complications of the required immunosuppressive drug therapy. Bioartificial pancreas offer a potential solution by providing immunoprotection to the contained islet tissue. This would allow the use of xenogeneic islet tissue without the need for immunosuppression. The PI has developed a cell containment device which has been shown to: 1) immunoisolate xenogeneic islets from the host, 2) allow the islets to produce insulin and remain viable for up to 43 days, 3) easily exchange islets within the device without surgical intervention to maintain its function, 4) avoid encapsulation of the device. This Phase I proposal will prove feasibility of the device for use with porcine islets in achieving euglycemia in research dogs to assess the efficiency of naked vs. microencapsulated islets when used with this device.